IXICO plc - IXICO and NYU Langone Health sign agreement

RNS Number : 3150C
16 October 2020


This is an RNS Reach announcement and the information contained is not considered to be material or to have a significant impact on management's expectations of the Group's performance. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach."



("IXICO" or the "Company")


IXICO and NYU Langone Health sign agreement to develop

novel imaging markers in multiple system atrophy


IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that it has entered into an agreement with NYU Langone Health to support a trial to determine if the immunosuppressant drug Sirolimus - approved by the FDA to prevent organ transplant rejection and for the treatment of a rare and progressive lung disease called lymphangioleiomiomatosis - is also able to slow the progression of disease in people with Multiple System Atrophy (MSA). Working with NYU Langone clinicians and researchers, the trial will help develop biomarkers for MSA from magnetic resonance imaging (MRI).


MSA is a condition of the central nervous system that causes gradual damage to nerve cells in the brain. The project involves application of IXICO's existing MSA analysis solutions on retrospectively collected MRI data from patients with MSA, dementia with Lewy Bodies, Parkinson's disease, and Progressive Supranuclear Palsy as well as the joint development of a novel solution to analyse susceptibility weighted imaging (SWI).


Dr Robin Wolz, Senior Vice President for Science and Innovation at IXICO plc, commented: "This collaboration will help to accelerate the quest for new treatments for Multiple System Atrophy by bringing together some of the leading researchers in the field from both academia and industry with the specific goal of developing new tools to better understand and characterise this debilitating disease."


Dr. Horacio Kaufman, the Felicia B. Axelrod Professor of Dysautonomia Research at NYU Grossman School of Medicine and Director of the Dystonomia Center at NYU Langone Health, added: "IXICO will bring its expertise in neuroimaging and AI to support the development and validation of new biomarkers which in turn will help to identify the most promising treatments and bring these to patients sooner." 


For further information please contact:



+44 (0)20 3763 7498

Giulio Cerroni, Chief Executive Officer

Grant Nash, Chief Financial Officer



Cenkos Securities PLC (Nominated adviser and sole broker)

+44 (0)20 7397 8900

Giles Balleny / Max Gould (Corporate Finance)


Michael F Johnson / Russell Kerr (Sales)



Walbrook PR Ltd

+44 (0)20 7933 8780


Paul McManus / Lianne Cawthorne /


Alice Woodings



IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.


More information is available on www.IXICO.com and follow us on Twitter @IxicOplc 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

Quick facts: IXICO PLC


Price: 81.5

Market Cap: £39.24 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Ixico seeing success with a number of contracts awarded covering multiple...

Ixico plc Chief Commercial Officer Lammert Albers joined Steve Darling from Proactive to share news the Clinical Research Organization has awarded the company, on behalf of their biopharmaceutical sponsor,  a 6-figure deal to conduct a Phase II Alzheimer’s disease clinical trial.  Albers...

1 day, 15 hours ago

4 min read